Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Genome Sequencing Is Mapping a Path to Personalized Treatment for Ovarian Cancer

August 17th 2016

Genome sequencing studies have uncovered an array of distinct genomic drivers underlying various ovarian cancer subtypes. If researchers can capitalize on these discoveries, it may offer a path to more individualized and effective treatment options.

What Is a Patient Who Refuses Chemotherapy Really Saying?

August 15th 2016

Although chemotherapy has changed dramatically since it was introduced, platinum-containing combinations remain standard in ovarian cancer. Often, the established regimen can be modified for patients who quite justifiably may fear the toxicities of platinum agents.

"Stemness" Inhibitor Demonstrates Activity in Patients With Advanced Ovarian Cancer

August 12th 2016

Results of an early phase trial show that, for heavily pretreated patients with platinum-resistant ovarian cancer, a first-in-class cancer "stemness" inhibitor that targets the STAT3 pathway was found to demonstrate antitumor activity—and was also found to be well tolerated when combined with paclitaxel.

Dr. Leslie Randall Discusses Evidence Supporting BRCA Testing in Ovarian Cancer

August 10th 2016

Leslie M. Randall, MD, associate professor of Gynecology/ Oncology, University of California Irvine, discusses evidence supporting the use of BRCA testing for patients with ovarian cancer.

Rucaparib's Efficacy in Ovarian Cancer Determined With Novel Biomarker

August 9th 2016

While BRCA status continues to be a predictive indicator of response to rucaparib for patients with ovarian cancer, loss of genomic heterozygosity was shown to also be an effective biomarker for predicting outcomes.

ASCO Issues New Guideline for Neoadjuvant Chemotherapy in Ovarian Cancer

August 8th 2016

Neoadjuvant chemotherapy is the optimal first-line treatment for some women with newly diagnosed, advanced ovarian cancer.

Dr. Robert Coleman on the Importance of BRCA Testing in Ovarian Cancer

August 4th 2016

Robert Coleman, MD a professor in the Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses the importance of BRCA testing for patients diagnosed with ovarian cancer.

Researcher Discusses Role for Maintenance Olaparib in Ovarian Cancer

August 3rd 2016

Charlie Gourley, PhD, MBChB, discusses the potential use of olaparib (Lynparza) as a maintenance therapy for patients with ovarian cancer.

Silence on Ovarian Cancer Trial Debacle Is Disheartening

July 22nd 2016

A phase III trial in ovarian cancer was allowed to continue even as the patients who received the experimental study drug were experiencing strikingly inferior outcomes compared with participants on standard therapy. The lack of answers about this trial remains a glaring example of shortcomings in the research paradigm.

Early Assessment of BRCA Status Key in Ovarian Cancer, Two Experts Agree

July 19th 2016

Robert Coleman, MD, and Leslie Randall, MD, provide further insight on the importance of BRCA testing.

Avelumab Shows Promise in Early Trial for Advanced Ovarian Cancer

July 19th 2016

Avelumab, a fully human anti–PD-L1 IgG1 antibody, showed activity in patients with heavily pretreated recurrent or refractory ovarian cancer with an acceptable toxicity profile.

Risks for Breast, Ovarian Cancers Could Be Found With Multigene Panel Testing

July 14th 2016

Allison W. Kurian, MD, MSc, discusses 2 clinical trials utilizing multigene panels to uncover previously undetected risks in patients with breast and ovarian cancer.

Dr. Kurian on Association of Ovarian Cancer Risk With Mutations Detected by Multiple-Gene Germline Sequencing

July 6th 2016

Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses an ongoing trial exploring the association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women.

Maintenance Niraparib Improves PFS in Ovarian Cancer

June 29th 2016

Maintenance therapy with niraparib improved progression-free survival compared with placebo for patients with recurrent ovarian cancer harboring a germline BRCA mutation or homologous recombination deficiency.

Survival Benefit Observed With Olaparib in Ovarian Cancer

June 9th 2016

In patients with platinum-sensitive relapsed serous ovarian cancer, olaparib (Lynparza) was found to significantly increase overall survival when given as maintenance therapy.

Study Confirms Adjuvant Intraperitoneal Chemotherapy Is Beneficial and Well Tolerated

June 4th 2016

Intraperitoneal chemotherapy is beneficial and tolerable, and physicians should present it as an option to women who have had successful cytoreductive surgery for their advanced epithelial ovarian cancer.

Ovarian Cancer Study Fails to Settle Debate Over Chemotherapy Regimens

April 22nd 2016

Intraperitoneal therapy was not superior to intravenous treatment when used in combination with bevacizumab (Avastin) as a regimen for patients with advanced ovarian cancer.

MEK Inhibitor Misses Mark in Phase III Ovarian Cancer Study

April 1st 2016

The MEK inhibitor binimetinib failed to improve progression-free survival compared with physician's choice of chemotherapy for patients with low-grade serous ovarian cancer.

Trial of Ovarian Chemotherapy Regimens Fails to Provide Clarity

March 22nd 2016

Three different chemotherapy regimens, each combined with bevacizumab, failed to demonstrate an advantage for patients with advanced ovarian cancer or build on results of a landmark trial reported more than a decade ago.

Phase III Studies Aim to Expand Olaparib's Ovarian Cancer Approval

March 22nd 2016

Ursula A. Matulonis, MD, discusses ongoing developments with olaparib, as well as the overall future of PARP inhibitors in ovarian cancer.